Bridgepoint mulls Aenova exit

The company, if sold, could fetch around €400m according to reports that predict an auction in the third quarter of 2012.

However, the GP did not confirm a planned sale. James Murray, partner at Bridgepoint, told unquote": "We are in the process of appointing Morgan Stanley to advise on options for the company in the next 12 months."

Murray confirmed the company expected to yield an EBITDA of around €50m this year. Aenova posted a €262m turnover and €43.2m of pre-tax earnings in 2011.

Bridgepoint formed Aenova in 2008 by merging Swiss Caps, which it acquired in 2005, and German contract manufacturer Dragenopharm, acquired in 2007.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Healthcare
• Bridgepoint